Treatment response and survival in patients with 
tumours, SD, PD‐L1
TUMOURS, DISEASE
The 15 participating patients with PD‐L1 negative tumours had a median of 10 infusions of atezolizumab. As the best overall response, two patients achieved a partial response and seven had SD, creating an objective response rate (ORR) of 13% and a disease control rate of 60%. Median PFS was 4.1 months. Six PD‐L1 negative patients were on treatment and considered clinically benefitting from therapy for more than 1 year, although three of them were treated beyond radiologic progression. Median OS time was still not reached at the data cut‐off, but 10 out of the 15 patients were alive more than 18 months after the start of the study treatment.